Compare TARA & NUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TARA | NUS |
|---|---|---|
| Founded | N/A | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.1M | 266.5M |
| IPO Year | 2014 | 1996 |
| Metric | TARA | NUS |
|---|---|---|
| Price | $3.84 | $4.72 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $24.40 | N/A |
| AVG Volume (30 Days) | 367.3K | ★ 558.0K |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 3.36% |
| EPS Growth | 38.25 | ★ 207.80 |
| EPS | ★ N/A | N/A |
| Revenue | $2,948,000.00 | ★ $3,176,718,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 48.98 |
| 52 Week Low | $3.02 | $4.49 |
| 52 Week High | $7.82 | $14.62 |
| Indicator | TARA | NUS |
|---|---|---|
| Relative Strength Index (RSI) | 39.68 | 38.71 |
| Support Level | $3.73 | $4.49 |
| Resistance Level | $4.20 | $5.51 |
| Average True Range (ATR) | 0.15 | 0.24 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 15.19 | 21.29 |
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
Nu Skin Enterprises Inc develops and distributes a comprehensive line of beauty and wellness solutions in various countries. The company operates in two primary product categories: beauty and wellness products. Additionally, the company also operates through its subsidiary, Rhyz. It reports revenue from nine segments, consisting of its seven geographic Nu Skin segments: Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan and two Rhyz segments: manufacturing, which includes manufacturing and packaging subsidiaries it has acquired; and Rhyz Other, which includes other investments by its Rhyz strategic investment arm. The majority of the company's revenue is generated from the Wellness product category from the Americas segment.